

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 3 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 5 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 6 MAY 30 INPAFAMDB now available on STN for patent family searching
NEWS 7 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 9 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 10 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11 JUN 19 CAS REGISTRY includes selected substances from web-based collections
NEWS 12 JUN 25 CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 17 JUL 28 CA/CAplus patent coverage enhanced
NEWS 18 JUL 28 EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20 JUL 28 STN Viewer performance improved
NEWS 21 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22 AUG 13 CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 24 AUG 15 CAplus currency for Korean patents enhanced
NEWS 25 AUG 25 CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26 AUG 27 CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:45:11 ON 03 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:45:18 ON 03 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 SEP 2008 HIGHEST RN 1045894-64-1
DICTIONARY FILE UPDATES: 2 SEP 2008 HIGHEST RN 1045894-64-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10596745s2.str



```
chain nodes :  
1 2 3 4 5 6 7 8 10 12  
chain bonds :  
1-3 1-2 3-4 4-5 5-6 6-7 7-8 7-10 10-12  
exact/norm bonds :  
1-3 1-2 4-5 5-6 6-7 7-8 7-10 10-12  
exact bonds :  
3-4
```

G1:C,N

G2:C,O,N

```
Match level :  
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:CLASS 7:CLASS 8:CLASS 10:CLASS  
12:Atom  
Generic attributes :  
5:  
Saturation : Unsaturated  
Type of Ring System : Monocyclic  
12:  
Saturation : Unsaturated  
Type of Ring System : Monocyclic  
  
Element Count :  
Node 1: Limited  
N,N2  
C,C4
```

L1 STRUCTURE UPLOADED

```
=> s l1 sss sam  
SAMPLE SEARCH INITIATED 14:45:33 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 12389 TO ITERATE
```

16.1% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 241111 TO 254449
PROJECTED ANSWERS: 36 TO 458

L2 2 SEA SSS SAM L1

=> s c4n2/rf
L3 2493185 C4N2/RF

=> s l1 sub=l2 sam
SAMPLE SUBSET SEARCH INITIATED 14:45:53 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 2 TO 124
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 2 TO 124

L4 2 SEA SUB=L2 SSS SAM L1

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:46:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12389 TO ITERATE


16.1% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 241111 TO 254449
PROJECTED ANSWERS: 36 TO 458

L5 2 SEA SSS SAM L1

=> d scan


L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-
MF C20 H17 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyrimidinyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-
MF C18 H18 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss full
FULL SEARCH INITIATED 14:47:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 249108 TO ITERATE

100.0% PROCESSED 249108 ITERATIONS 215 ANSWERS
SEARCH TIME: 00.00.03

L6 215 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
SESSION
FULL ESTIMATED COST ENTRY 184.89 185.10

FILE 'CAPLUS' ENTERED AT 14:47:35 ON 03 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Sep 2008 VOL 149 ISS 10
FILE LAST UPDATED: 2 Sep 2008 (20080902/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 16

L7

5 L6

```
=> d ibib abs hitsrt 1-5  
'HITSRT' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERM  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PAT5 ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
          SCAN must be entered on the same line as the DISPLAY,  
          e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
              containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
              its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
              structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
              its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
              structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):d ibib abs hitstr 1-5
'D' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
 SCAN must be entered on the same line as the DISPLAY,
 e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.



All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:792996 CAPLUS
 DOCUMENT NUMBER: 145:211064
 TITLE: Preparation of pyrimidine derivatives and their use as Tie2 receptor tyrosine kinase inhibitors
 INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
 SOURCE: PCT Int. Appl., 116pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082404	A1	20060810	WO 2006-GB352	20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1848715	A1	20071031	EP 2006-709603	20060202
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007DN05606	A	20070817	IN 2007-DN5606	20070719
US 20080153838	A1	20080626	US 2007-815523	20070803
CN 101155807	A	20080402	CN 2006-80011279	20071008
PRIORITY APPLN. INFO.:			GB 2005-2418	A 20050205
			WO 2006-GB352	W 20060202
OTHER SOURCE(S):	CASREACT 145:211064; MARPAT 145:211064			
GI				



AB Substituted heterocyclic and heteroaryl derivs. I, wherein A is an aryl or 5 or 6 membered heteroaryl ring; B is a cycloalkyl 3 to 7 membered heterocycle, aryl, 5 or 6 membered heteroaryl or an 8-10 membered bicyclic; D is a 5 or 6 membered nitrogen containing heteroaryl optionally substituted by oxygen, nitrogen or sulfur atoms; L is attached meta or para on the ethynyl group of A by a (un)substituted amide, (un)substituted carbamate, sulfonate, sulfonamide, a direct bond, or bound to an O or an (un)substituted N; R1 is H, hydroxy, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted cycloalkyl, (un)substituted heteroaryl or heterocyclic ring, (un)substituted amine; R2 is halo, cyano, alkoxy, cyclopropyl, alkyl, where the alkoxy or alkyl groups are optionally substituted by cyano or 1 or more fluoro groups; L is meta or para attached by an (un)substituted amide, (un)substituted amine, alkyl group; R3 is halo, cyano, oxo, cycloalkyl, 3 to 7 membered heterocycle; m, n, p are 0-3 are prepared and used as medicaments and in the production of

an

anti-angiogenic effect in a warm blooded animal. Thus, II was prepared and tested as an in vitro inhibitor of the Tie2 receptor tyrosine kinase and in the inhibition of autophosphorylation of Tie2 receptor tyrosine kinase (IC₅₀ are 2.6 and 0.031 μM resp.). Further, I can be used in the treatment of cancer and as antineoplastic prodrugs.

IT 905286-90-0P 905286-92-2P 905286-95-5P


905286-96-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)


RN 905286-90-0 CAPLUS

CN Urea, N-[3-[2-(5-amino-2-pyrazinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 905286-92-2 CAPLUS

CN Urea, N-[3-[2-(6-amino-3-pyridazinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 905286-95-5 CAPLUS


CN Acetamide, N-[5-[2-[3-[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrazinyl]- (CA INDEX NAME)



RN 905286-96-6 CAPLUS

CN Acetamide, N-[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrazinyl]-2-(2-methoxyethoxy)-(CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— CH₂ — OMe



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:790854 CAPLUS
 DOCUMENT NUMBER: 145:230644
 TITLE: Preparation of pyrimidine derivatives and their use as Tie2 receptor tyrosine kinase inhibitors
 INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
 SOURCE: PCT Int. Appl., 168pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082373	A1	20060810	WO 2006-GB284	20060127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1863805 A1 20071212 EP 2006-701245 20060127
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2008528663 T 20080731 JP 2007-553683 20060127
 IN 2007DN05604 A 20070817 IN 2007-DN5604 20070719
 CN 101137652 A 20080305 CN 2006-80007855 20070911
 PRIORITY APPLN. INFO.: GB 2005-1984 A 20050201
 GB 2005-2417 A 20050205
 GB 2005-12614 A 20050621
 WO 2006-GB284 W 20060127

OTHER SOURCE(S): MARPAT 145:230644
GI




AB Substituted pyrimidine derivs. I, wherein R1 is an (un)substituted amine, (un)substituted 3-7 membered heterocyclic ring; R2 and R3 are H, (un)substituted alkyl, (un)substituted alkoxy; A is a 5 or 6 membered heteroaryl ring; R4 is halo, cyano, alkoxy, cyclopropyl, alkyl, where the alkoxy or alkyl groups are optionally substituted by cyano or 1 or more fluoro groups; L is meta or para attached by an (un)substituted amide, (un)substituted amine, alkyl group; B is a cycloalkyl, heterocyclic ring, aryl, heteroaryl, bicyclic ring; R5 is a halo, hydroxyl, amino, alkylamino, cyano, cycloalkyl ring, an (un)substituted 3 to 7 membered heterocyclic ring; m and n are 0-3 are prepared and used as medicaments and in the production of an anti-angiogenic effect in a warm blooded animal. Thus, II was prepared and tested as an in vitro inhibitor of the Tie2 receptor tyrosine kinase and in the inhibition of autophosphorylation of Tie2 receptor tyrosine kinase (IC50 are 1.5 and 1.9 μM resp.). Further, I can be used in the treatment of cancer and as antineoplastic prodrugs.

IT 857265-17-9P, Phenyl[3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857266-46-7P, Phenyl 3-[(2-[(dimethylamino)propyl]amino)pyrimidin-5-yl]ethynyl]phenylcarbamate 857287-13-9P, Phenyl[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 905439-39-6P 905439-44-3P 905439-48-7P 905439-61-4P 905439-64-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)


RN 857265-17-9 CAPLUS

CN Carbamic acid, [3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857266-46-7 CAPLUS

CN Carbamic acid, [3-[[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857287-13-9 CAPLUS

CN Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-39-6 CAPLUS

CN Carbamic acid, [5-[(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-44-3 CAPLUS

CN Carbamic acid, [4-methyl-3-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-48-7 CAPLUS

CN Carbamic acid, [6-methyl-5-[[2-[(2-(4-morpholinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905439-61-4 CAPLUS

CN Carbamic acid, [5-[[2-[(2-(4-morpholinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



RN 905439-64-7 CAPLUS

CN Carbamic acid, [5-[[2-[(3-(4-morpholinyl)propyl)amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:381241 CAPLUS
 DOCUMENT NUMBER: 144:432828
 TITLE: Heteroaryl-substituted alkyne compounds as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Chaffee, Stuart C.; Albrecht, Brian K.; Hodous, Brian L.; Martin, Matthew W.; McGowan, David C.; Dimauro, Erin F.; Reddy, Gade; Cee, Victor J.; Olivieri, Philip R.; Reed, Anthony; Romero, Karina
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 330 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044823	A2	20060427	WO 2005-US37299	20051017
WO 2006044823	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060217380	A1	20060928	US 2005-251490	20051014
AU 2005295414	A1	20060427	AU 2005-295414	20051017
CA 2583907	A1	20060427	CA 2005-2583907	20051017
EP 1802586	A2	20070704	EP 2005-812237	20051017
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,				

BA, HR, MK, YU
PRIORITY APPLN. INFO.:

US 2004-620100P P 20041018
US 2005-251490 A 20051014
WO 2005-US37299 W 20051017

OTHER SOURCE(S): MARPAT 144:432828
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to heteroaryl-substituted alkynes of formula I, which are protein kinase modulators. In compds. I, W, X, Y, and Z are independently selected from N and (un)substituted C; R1 is (un)substituted amino, acyl, acyloxy, carboxylate, carbamoyl, thiocarbamoyl, etc.; and R2 is 5- to 8-membered monocyclic, 6- to 12-membered bicyclic, or 7- to 14-membered tricyclic ring system, optionally including 1-3 heteroatoms selected from O, N, and S; including stereoisomers, tautomers, solvates, salts, derivs., and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the prophylaxis and treatment of protein kinase-mediated diseases, including inflammation, cancer and related conditions. Chlorination of 3-iodo-4-methylbenzoic acid and amidation with 3-trifluoromethylaniline gave benzamide II, which underwent coupling with 2-amino-5-ethynylpyrimidine (preparation from 2-amino-5-iodopyrimidine and trimethylsilylacetylene is given) to give pyrimidinylalkyne III. Several compds. of the invention, e.g., III, express IC₅₀ values of less than or equal to 10 μM both for Tie-2 and Lck kinase.


IT 884602-98-6P, N-[4-[2-(2-Aminopyrimidin-5-yl)ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)urea 884603-00-3P
884604-13-1P, N-[3-Methyl-4-[[4-[[2-(methyoxy)phenyl]oxy]-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroaryl-substituted alkynes as protein kinase modulators)


RN 884602-98-6 CAPLUS

CN Urea, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 884603-00-3 CAPLUS


CN Urea, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-methylphenyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)



RN 884604-13-1 CAPLUS

CN Urea, N-[4-[2-[4-(2-methoxyphenoxy)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-pyrimidinyl]ethynyl]-3-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)-(CA INDEX NAME)

PAGE 1-A



PAGE 1-B

Me

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:588668 CAPLUS

DOCUMENT NUMBER: 143:115557

TITLE: Preparation of 2-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases

Jones, Clifford David; Luke, Richard William Arthur; McCoull, William

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 178 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060970	A1	20050707	WO 2004-GB5337	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 EP 1737463 A1 20070103 EP 2004-806139 20041220
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 CN 1917879 A 20070221 CN 2004-80041901 20041220
 JP 2007517007 T 20070628 JP 2006-546306 20041220
 US 20080108608 A1 20080508 US 2006-596745 20060622
 IN 2006MN00846 A 20070608 IN 2006-MN846 20060717
 PRIORITY APPLN. INFO.: GB 2003-30000 A 20031224
 GB 2004-16849 A 20040729
 WO 2004-GB5337 W 20041220

OTHER SOURCE(S): MARPAT 143:115557
GI




AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, 2-amino-5-iodopyrimidine underwent Pd-catalyzed coupling with 3-ethynylaniline in the presence of CuI. The resultant substituted aniline was condensed with a carbamate, which was obtained from Ph chloroformate and 5-amino-3-methylisoxazole, to give urea II. This compound showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC₅₀ values of 19.871 μM and 0.337 μM, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.

IT 857265-16-8P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-17-9P, Phenyl [3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857265-31-7P, N-[3-[[2-[(2-Aminoethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-32-8P, N-[3-[[2-[(3-Aminopropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-46-7P, Phenyl [3-[[2-[(3-dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]carbamate
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857265-16-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-17-9 CAPLUS

CN Carbamic acid, [3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857265-31-7 CAPLUS

CN Urea, N-[3-[2-[2-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-32-8 CAPLUS

CN Urea, N-[3-[2-[2-[(3-aminopropyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857266-46-7 CAPLUS

CN Carbamic acid, [3-[2-[(3-(dimethylamino)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



IT 857264-91-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea 857264-93-8P,
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)urea 857264-94-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)urea
 857264-95-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-fluorophenyl)urea 857264-96-1P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-fluorophenyl)urea 857264-97-2P,
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-fluorophenyl)urea
 857264-98-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea 857264-99-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,5-difluorophenyl)urea 857265-01-1P,
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea 857265-02-2P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-methoxyphenyl)urea
 857265-03-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-methoxyphenyl)urea 857265-04-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-difluorophenyl)urea 857265-05-5P,
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-cyanophenyl)urea
 857265-06-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-chlorophenyl)urea 857265-08-8P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,5-difluorophenyl)urea 857265-09-9P,
 N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butyl-1,3,4-thiadiazol-2-yl)urea 857265-13-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857265-14-6P,
 N-[3-[[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857265-15-7P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)pyridin-2-yl)urea
 857265-18-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-oxopiperidin-3-yl)urea 857265-19-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(methylamino)pyrimidin-5-yl]ethynyl]phenyl]urea
 857265-22-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(dimethylamino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-23-7P,
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-24-8P,
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-(morpholin-4-yl)propyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-25-9P,
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-methoxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-26-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-(1H-imidazol-1-yl)propyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-27-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-methoxypropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea
 857265-28-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(hydroxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-29-3P,
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(pyrrololidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-30-6P,
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-pyrrololidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-33-9P,
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(dimethylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-34-0P,
 N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-35-1P,
 N-[5-[[3-[[5-tert-Butylisoxazol-3-yl]amino]carbonyl]amino]phenyl]ethynyl]pyrimidin-2-yl]glycinamide 857265-36-2P 857265-37-3P,

N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[[2-[2-(1H-imidazol-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-38-4P,
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[[2-[2-(pyridin-2-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-39-5P,
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[[2-[3-(isopropylamino)propyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-40-8P,
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[[2-[3-(4-methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-41-9P,
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[[2-[2-(pyridin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-42-0P,
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[[2-[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-43-1P,
N-(5-Methylisoxazol-3-yl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-47-5P,
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-48-6P,
N-(3-Methylisothiazol-5-yl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-49-7P,
N-(3-Fluorophenyl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-50-0P, N-(4-Methoxyphenyl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-51-1P, N-(2-Fluorophenyl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-52-2P,
N-(2,5-Difluorophenyl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-53-3P,
N-(3,4-Difluorophenyl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-54-4P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-55-5P,
N-[3-[[2-[2-(Pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl]urea 857265-57-7P,
N-(4-Fluorophenyl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-58-8P, N-(3-Chlorophenyl)-N'-(3-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-59-9P, N-(5-Methylisoxazol-3-yl)-N'-(3-[[2-[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-60-2P,
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[[2-[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-61-3P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[[2-[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-62-4P,
N-(5-Methylisoxazol-3-yl)-N'-(3-[[2-[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-63-5P,
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[[2-[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-64-6P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[[2-[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-65-7P,
N-(5-Methylisoxazol-3-yl)-N'-(4-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-68-0P,
N-(5-tert-Butylisoxazol-3-yl)-N'-(4-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-69-1P,
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(4-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-70-4P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-(4-[[2-[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl)phenyl]urea 857265-71-5P,
N-[5-[[3-[(5-tert-Butylisoxazol-3-yl)amino]carbonyl]amino]phenyl]ethynyl]pyrimidin-2-yl]-2-(2-methoxyethoxy)acetamide 857265-72-6P,
N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-2-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-76-0P, N-[2-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-4-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-78-2P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea 857265-80-6P,
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(2-fluoro-

5-(trifluoromethyl)phenyl]urea 857265-82-8P,
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-84-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-85-1P,
2-Phenyl-N-[3-[2-(2-aminopyrimidin-5-yl)ethynyl]phenyl]acetamide 857265-86-2P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857265-87-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857265-88-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 857265-89-5P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methylisoxazol-5-yl)acetamide 857265-91-9P, N-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-92-0P,
N-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methylisoxazol-5-yl)acetamide 857265-94-2P, N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyrimidin-4-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-96-4P, N'-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-(5-tert-butylisoxazol-3-yl)-N-methylurea 857265-97-5P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea 857265-98-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-tert-butyl-3-cyclopropyl-1H-pyrazol-5-yl)urea 857265-99-7P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)urea 857266-00-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)urea 857266-01-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-isopropyl-1,3,4-thiadiazol-2-yl)urea 857266-02-5P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-tert-butyl-1,3-thiazol-2-yl)urea 857266-03-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-methylisoxazol-3-yl)urea 857266-04-7P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)urea 857266-05-8P, N'-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea 857266-06-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)urea 857266-07-0P, N-Phenyl-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-09-2P,
N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-10-5P,
N-[3-[[2-[[3-(Piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(4-(trifluoromethyl)pyridin-2-yl)urea 857266-11-6P,
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-12-7P,
N-(3-Methylisoxazol-5-yl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-13-8P,
N-(2-Methoxyphenyl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-14-9P, N-(3-Fluorophenyl)-N'-[3-[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-15-0P, N-[3-[[2-[(4-Aminobutyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-16-1P
, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(piperidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-17-2P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(isopropylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-18-3P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(hydroxyethoxy)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-19-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[4-(dimethylamino)butyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-20-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(dimethylamino)-1-methylethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-21-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[1-methyl-2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-22-9P 857266-25-2P 857266-26-3P,


N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[2-(piperazin-1-yl)ethyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-27-4P,
N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[3-(piperazin-1-yl)propyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-29-6P,
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-(3-[2-[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-32-1P,
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-(3-[2-[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-33-2P,
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-(3-[2-[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-34-3P,
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-36-5P,
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-37-6P,
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl)ethynylphenyl]urea 857266-38-7P,
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[2-(dimethylamino)ethyl]amino]pyrimidin-5-yl)ethynylphenyl]urea
857266-39-8P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[2-(isopropylamino)ethyl]amino]pyrimidin-5-yl)ethynylphenyl]urea
857266-40-1P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl)ethynylphenyl]urea
857266-42-3P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl)ethynylphenyl]urea
857266-43-4P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl)ethynylphenyl]urea
857266-44-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[2-(2-hydroxy-1-oxoethyl)amino]ethyl]amino)pyrimidin-5-yl)ethynylphenyl]urea
857266-45-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[2-[3-(2-hydroxyethyl)amino]propyl]amino)pyrimidin-5-yl)ethynylphenyl]urea
857266-48-9P, N-[3-[2-[3-(Dimethylamino)propyl]amino]pyrimidin-5-yl]ethynylphenyl]-N'-phenylurea 857266-49-0P,
N-[3-[2-[3-(Dimethylamino)propyl]amino]pyrimidin-5-yl]ethynylphenyl]-N'-
(5-methylisoxazol-3-yl)urea 857266-50-3P, N-(5-tert-
Butylisoxazol-3-yl)-N'-(3-[2-[3-(dimethylamino)propyl]amino]pyrimidin-5-yl)ethynylphenyl]-N-methylurea 857266-51-4P,
N'-(4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl)-N-(5-tert-butylisoxazol-3-yl)-N-methylurea 857266-53-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)-N-methylurea
857266-57-0P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-61-6P,
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-63-8P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-64-9P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-phenylurea 857266-67-2P,
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-70-7P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-74-1P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenylurea 857266-82-1P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)urea 857266-84-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-(ethylthio)-1,3,4-thiadiazol-2-yl)urea
857266-86-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-88-7P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 857266-90-1P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-tert-butyl-1H-pyrazol-4-yl)urea
857266-93-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-96-7P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-isopropyl-1,3,

oxadiazol-2-yl)urea 857266-99-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)urea 857267-02-8P
 , N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-isopropyl-1H-pyrazol-3-yl)urea 857267-06-2P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-[3-fluoro-5-(4-methylpiperazin-1-yl)phenyl]urea 857267-09-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]-4-methylphenyl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857264-91-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857264-93-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857264-94-9 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857264-95-0 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)




RN 857264-96-1 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-fluorophenyl)-
(CA INDEX NAME)




RN 857264-97-2 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-fluorophenyl)-
(CA INDEX NAME)



RN 857264-98-3 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methoxyphenyl)-
(CA INDEX NAME)




RN 857264-99-4 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,5-difluorophenyl)-
(CA INDEX NAME)




RN 857265-01-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857265-02-2 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)




RN 857265-03-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 857265-04-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 857265-05-5 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyanophenyl)- (CA INDEX NAME)




RN 857265-06-6 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-chlorophenyl)-
(CA INDEX NAME)




RN 857265-08-8 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,5-difluorophenyl)-
(CA INDEX NAME)




RN 857265-09-9 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-
(CA INDEX NAME)




RN 857265-13-5 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)-
(CA INDEX NAME)




RN 857265-14-6 CAPLUS
CN Acetamide, N-[3-[[[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]amino]carbo-
nyl]amino]phenyl]- (CA INDEX NAME)




RN 857265-15-7 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-
(trifluoromethyl)-2-pyridinyl)- (CA INDEX NAME)




RN 857265-18-0 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-oxo-3-
piperidinyl)- (CA INDEX NAME)




RN 857265-19-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-(methylamino)-5-
pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-22-6 CAPLUS
CN Urea, N-[3-[2-(dimethylamino)-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-
dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857265-23-7 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-24-8 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-25-9 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(2-methoxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-26-0 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-(1H-imidazol-1-yl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-27-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(3-methoxypropyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-28-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(2-hydroxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-29-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(2-(1-pyrrolidinyl)ethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-30-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(3-(1-pyrrolidinyl)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-33-9 CAPLUS


CN Urea, N-[3-[2-[2-[(2-(dimethylamino)ethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857265-34-0 CAPLUS
 CN Urea, N-[3-[2-[2-[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857265-35-1 CAPLUS
 CN Acetamide, 2-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino- (CA INDEX NAME)




RN 857265-36-2 CAPLUS
 CN Propanamide, 3-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino- (CA INDEX NAME)




RN 857265-37-3 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(1H-imidazol-5-yl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857265-38-4 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(2-pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-39-5 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-(1-methylethyl)aminopropyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-40-8 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


 Me
 RN 857265-41-9 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-(4-pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)




RN 857265-42-0 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-43-1 CAPLUS
 CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-47-5 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-48-6 CAPLUS
 CN Urea, N-(3-methyl-5-isothiazolyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-49-7 CAPLUS

CN Urea, N-(3-fluorophenyl)-N'-(3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-50-0 CAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-(3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-51-1 CAPLUS

CN Urea, N-(2-fluorophenyl)-N'-(3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-52-2 CAPLUS

CN Urea, N-(2,5-difluorophenyl)-N'-(3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-53-3 CAPLUS

CN Urea, N-(3,4-difluorophenyl)-N'-(3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-54-4 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[2-[2-[(2-(1-pyrrolidinyl)ethyl]amino)-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857265-55-5 CAPLUS

CN Urea, N-[3-[2-[2-[(2-(1-pyrrolidinyl)ethyl]amino)-5-pyrimidinyl]ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857265-57-7 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-58-8 CAPLUS


CN Urea, N-(3-chlorophenyl)-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-59-9 CAPLUS
 CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[2-(4-morpholiny)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-60-2 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(4-morpholiny)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-61-3 CAPLUS
 CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[2-(4-morpholiny)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-62-4 CAPLUS
 CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[3-(4-

morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-63-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-(3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-64-6 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-(3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-65-7 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-(4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-68-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-69-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-(4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-70-4 CAPLUS


CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-(4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857265-71-5 CAPLUS

CN Acetamide, N-[5-[2-[3-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—OMe

RN 857265-72-6 CAPLUS


CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethyl]ethynyl]-2-pyridinyl-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857265-76-0 CAPLUS

CN Urea, N-[2-[2-(2-amino-5-pyrimidinyl)ethyl]ethynyl]-4-pyridinyl-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857265-78-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethyl]ethynyl]-2-thiazolyl-N'-(2-fluoro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857265-80-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 857265-82-8 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857265-84-0 CAPLUS


CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857265-85-1 CAPLUS
CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 857265-86-2 CAPLUS
CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 857265-87-3 CAPLUS
CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 857265-88-4 CAPLUS
CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857265-89-5 CAPLUS
CN 5-Isoxazoleacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methyl- (CA INDEX NAME)




RN 857265-91-9 CAPLUS
CN Benzeneacetamide, N-[4-[2-(2-amino-5-pyrimidinyl)ethyl]phenyl]-2-methoxy-
(CA INDEX NAME)



RN 857265-92-0 CAPLUS
CN 5-Isoxazoleacetamide, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methyl- (CA INDEX NAME)




RN 857265-94-2 CAPLUS
CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyrimidinyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 857265-96-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857265-97-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857265-98-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyclopropyl-1-(1,1-dimethylethyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857265-99-7 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-00-3 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-01-4 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)



RN 857266-02-5 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(1,1-dimethylethyl)-2-thiazolyl)- (CA INDEX NAME)




RN 857266-03-6 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-04-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857266-05-8 CAPLUS

CN Urea, N'-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857266-06-9 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-07-0 CAPLUS

CN Urea, N-phenyl-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-09-2 CAPLUS


CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-10-5 CAPLUS
 CN Urea, N-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(4-(trifluoromethyl)-2-pyridinyl)- (CA INDEX NAME)




RN 857266-11-6 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-(3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857266-12-7 CAPLUS
 CN Urea, N-(3-methyl-5-isoxazolyl)-N'-(3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857266-13-8 CAPLUS
 CN Urea, N-(2-methoxyphenyl)-N'-(3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857266-14-9 CAPLUS
 CN Urea, N-(3-fluorophenyl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-15-0 CAPLUS
 CN Urea, N-[3-[2-[2-[(4-aminobutyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857266-16-1 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(1-piperidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-17-2 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-[1-methylethyl]amino]ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-18-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(2-hydroxyethoxy)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—CH₂—OH


RN 857266-19-4 CAPLUS

CN Urea, N-[3-[2-[2-[4-(dimethylamino)butyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857266-20-7 CAPLUS

CN Urea, N-[3-[2-[2-[2-(dimethylamino)-1-methylethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857266-21-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[1-methyl-2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-22-9 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-[1-(2-hydroxyacetyl)-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-25-2 CAPLUS

CN Urea, N-[3-[2-[2-[1-[2-(dimethylamino)acetyl]-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


RN 857266-26-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[2-[1-(1-piperazinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 857266-27-4 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-(1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl)phenyl- (CA INDEX NAME)




RN 857266-29-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-(3-[2-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)



RN 857266-32-1 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-(3-[2-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl- (CA INDEX NAME)



RN 857266-33-2 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-(3-[2-[2-[2-[3-(1-

piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-34-3 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-36-5 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-37-6 CAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-38-7 CAPLUS


CN Urea, N-[3-[2-[2-[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-

5-y1]- (CA INDEX NAME)




RN 857266-39-8 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[2-[1-methylethyl]amino]ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-40-1 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857266-42-3 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-43-4 CAPLUS


CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857266-44-5 CAPLUS

CN Acetamide, N-[2-[5-[2-[3-[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—OH

RN 857266-45-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[3-[2-hydroxyethyl]amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)


PAGE 1-A



— CH₂— OH


RN 857266-48-9 CAPLUS

CN Urea, N-[3-[2-[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857266-49-0 CAPLUS

CN Urea, N-[3-[2-[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-50-3 CAPLUS

CN Urea, N'-[3-[2-[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857266-51-4 CAPLUS

CN Urea, N'-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)




RN 857266-53-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N-methyl- (CA INDEX NAME)




RN 857266-57-0 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857266-61-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 857266-63-8 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 857266-64-9 CAPLUS


CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-phenyl- (CA INDEX NAME)

INDEX NAME)




RN 857266-67-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-70-7 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-74-1 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenyl- (CA INDEX NAME)




RN 857266-82-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-84-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(ethylthio)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857266-86-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-88-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-90-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-(1,1-dimethylethyl)-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 857266-93-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-methyl-3-(1-methylethyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 857266-96-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1-methylethyl)-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)



RN 857266-99-0 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 857267-02-8 CAPLUS


CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-(1-methylethyl)-

1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 857267-06-2 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-fluoro-5-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 857267-09-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-methylphenyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)



IT 857266-23-0P, N-(5-tert-Butyloxazol-3-yl)-N'-(3-[(2-[(pyrrolidin-2-yl)methyl]amino)pyrimidin-5-yl]ethynyl]phenyl)urea

857266-24-1P, N-(5-tert-Butyloxazol-3-yl)-N'-(3-[(2-[(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl]amino)pyrimidin-5-yl]ethynyl]phenyl)urea


857266-52-5P, Phenyl [4-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857266-23-0 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[2-[(2-pyrrolidinylmethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857266-24-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857266-52-5 CAPLUS
 CN Carbamic acid, [4-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:588667 CAPLUS
 DOCUMENT NUMBER: 143:115556
 TITLE: Preparation of 4-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases
 INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060969	A1	20050707	WO 2004-GB5332	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 RW: TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 EP 1737462 A1 20070103 EP 2004-806134 20041220
 EP 1737462 B1 20080730
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 CN 1917880 A 20070221 CN 2004-80041936 20041220
 JP 2007517006 T 20070628 JP 2006-546305 20041220
 US 20080027076 A1 20080131 US 2006-596740 20060622
 IN 2006MN00847 A 20070420 IN 2006-MN847 20060717
 PRIORITY APPLN. INFO.: GB 2003-30001 A 20031224
 GB 2004-16850 A 20040729
 WO 2004-GB5332 W 20041220

OTHER SOURCE(S): CASREACT 143:115556; MARPAT 143:115556
 GI




AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, urea II was synthesized in 21% yield by condensation of the corresponding aniline with Ph thiadiazolylcarbamate in the presence of Et3N in THF under microwave irradiation. This urea showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC50 values of 0.879 μM and 5.557 μM, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.

IT 857287-13-9P, Phenyl [3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-53-7P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-(3-[(4-[(2-(morpholin-4-yl)ethyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857287-13-9 CAPLUS

CN Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 857287-53-7 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[4-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



IT 857287-02-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea 857287-04-8P, 2-Phenyl-N-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]acetamide 857287-05-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)urea 857287-06-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]urea 857287-07-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea 857287-08-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]urea 857287-09-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea 857287-10-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea 857287-11-7P, Phenyl [4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-14-0P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-15-1P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-16-2P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-17-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)pyridin-2-yl)urea 857287-18-4P, N-[3-[[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857287-19-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-20-8P, N-[3-[[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857287-21-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)pyridin-2-yl)urea 857287-22-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-


(3-methylisoxazol-5-yl)urea 857287-23-1P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-(3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl)urea 857287-24-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl)urea 857287-26-4P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-(morpholin-4-yl)phenyl)urea 857287-29-7P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857287-30-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857287-31-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 857287-32-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857287-35-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-(methylamino)pyrimidin-5-yl)ethynyl]phenyl)urea 857287-36-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-(isopropylamino)propyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-37-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(2-pyrrololidin-1-yl)ethyl]amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-38-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(5-tert-butylisoxazol-3-yl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-39-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(dimethylamino)propyl]amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-40-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(2-hydroxyethyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-41-3P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(2-(morpholin-4-yl)ethyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-42-4P, N-[3-[(4-[(4-Aminobutyl)amino]pyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-43-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(3-(pyrrololidin-1-yl)propyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-44-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(2,4-dimethoxybenzyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-45-7P, N-[3-[(4-[(2-Aminoethyl)amino]pyrimidin-5-yl)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-46-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(2-(dimethylamino)ethyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-47-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(4-[(dimethylamino)butyl]amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-48-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(2-(dimethylamino)ethyl)methylamino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-49-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(2-(piperidin-1-yl)ethyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-50-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(morpholin-4-yl)propyl]amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-51-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(3-(piperidin-1-yl)propyl)amino]pyrimidin-5-yl)ethynyl]phenyl)urea 857287-52-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-(3-[(4-[(4-methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl)ethynyl]phenyl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN


857287-02-6 CAPLUS

CN


Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857287-04-8 CAPLUS
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-05-9 CAPLUS
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 857287-06-0 CAPLUS
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-trifluoromethylphenyl)- (CA INDEX NAME)




RN 857287-07-1 CAPLUS
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-trifluoromethylphenyl)- (CA INDEX NAME)




RN 857287-08-2 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857287-09-3 CAPLUS
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 857287-10-6 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)




RN 857287-11-7 CAPLUS
CN Carbamic acid, [4-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857287-14-0 CAPLUS
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 857287-15-1 CAPLUS
 CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)



RN 857287-16-2 CAPLUS
 CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857287-17-3 CAPLUS
 CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857287-18-4 CAPLUS

CN Acetamide, N-[3-[[[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 857287-19-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)




RN 857287-20-8 CAPLUS

CN Acetamide, N-[3-[[[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 857287-21-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 857287-22-0 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857287-23-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857287-24-2 CAPLUS


CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-26-4 CAPLUS
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 857287-29-7 CAPLUS
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857287-30-0 CAPLUS
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 857287-31-1 CAPLUS
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857287-32-2 CAPLUS
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 857287-35-5 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-(methylamino)-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857287-36-6 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[3-[(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-37-7 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857287-38-8 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(5-(1,1-dimethylethyl)-3-isoxazolyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 857287-39-9 CAPLUS

CN Urea, N-[3-[2-[4-[(3-(dimethylamino)propyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-40-2 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[(2-hydroxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-41-3 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[(2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-42-4 CAPLUS
 CN Urea, N-[3-[2-[4-[(4-aminobutyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-43-5 CAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(1-pyrrolidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-44-6 CAPLUS
 CN Urea, N-[3-[2-[4-[(2,4-dimethoxyphenyl)methyl]amino]-5-

pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-45-7 CAPLUS

CN Urea, N-[3-[2-[4-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-46-8 CAPLUS

CN Urea, N-[3-[2-[4-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-47-9 CAPLUS


CN Urea, N-[3-[2-[4-[[4-(dimethylamino)butyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-48-0 CAPLUS


CN Urea, N-[3-[2-[4-[[2-(dimethylamino)ethyl]methylamino]-5-

pyrimidinyl]ethynyl]phenyl]-N'-(5-(1,1-dimethylethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 857287-49-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[[2-(1-piperidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-50-4 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)




RN 857287-51-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(3-[2-[4-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl)- (CA INDEX NAME)



RN 857287-52-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	28.21	213.31
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

STN INTERNATIONAL LOGOFF AT 14:48:48 ON 03 SEP 2008